Insulin resistance: Trigger or concomitant factor in the metabolic syndrome

Panminerva Medica

Volumn 48, Issue 1, 2006, Pages 3-12

  Avogaro, A ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b Policlinico Universitario   (Italy)

Author keywords

Insulin resistance; Metabolic syndrome; Risk factors

Indexed keywords

FATTY ACID;

BLOOD; CARDIOVASCULAR DISEASE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; METABOLIC SYNDROME X; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; STRESS;

CARDIOVASCULAR DISEASES; FATTY ACIDS, NONESTERIFIED; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; METABOLIC SYNDROME X; RISK FACTORS; STRESS;

EID: 33745037517     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
2. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998;47:1643-9.
3. Meigs. Metabolic Syndrome. In search of a clinical role. Diabetes Care 2004;27:2761-3.
4. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR et al. the 4S Group, the AFCAPS/TexCAPS Research Group: The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004;93:136-41.
5. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
6. Sundstrom J, Riserius U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006 Mar 20; [Epub ahead of print]
7. Alexander CM, Landsman PB, Teutsch SM, Haffner SM, Third National Health and Nutrition Examination Survey (NHANES III), National Cholesterol Education Program (NCEP). NCEP defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-4.
8. Yarnell JWG, Patterson CC, Bainton D, Sweetnam PM. Is metabolic syndrome a discrete entity in the general population? Evidence from the Caerphilly and Speedwell population studies. Heart 1998;79:248-52.
9. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Diabetes Care 2005;28:2289-304.
10. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11:327-32.
11. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-8.
12. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75:473-86.
13. Ferrannini E, Balkan B. Insulin: in search of a syndrome. Diabet Med 2002;19:724-9.
14. Meigs JM. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000;152:908-11.
15. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin-resistant. Ann Intern Med 2003;139:802-9.
16. Liao Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkins AJ et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004;27:978-83.
17. Hegele RA, Pollex RL. Genetic and physiological insights into the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 2005;289:R663-9.
18. Pierce M, Keen H, Bradley C. Risk of diabetes in offspring of parents with non-insulin-dependent diabetes. Diabet Med 1995;12:6-13.
19. Hattersley AT, Tooke JE. The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. Lancet 1999;353:1789-92.
20. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333-46.
21. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001;86:713-8.
22. Bonadonna RC, Stumvoll M, Fritsche A, Muggeo M, Haring H, Bonora E et al. Altered homeostatic adaptation of first- and secondphase beta-cell secretion in the offspring of patients with type 2 diabetes: studies with a mini minimal model to assess beta-cell function. Diabetes 2003;52:470-80.
23. Unger RH. Lipotoxicity in the pathogenesis of obesity dependent NIDDM: genetic and clinical implications. Diabetes 1995;44:863-70.
24. Stout RW. Hyperinsulinemia and atherosclerosis. Diabetes 1996;45 Suppl 3:S45-6.
25. Ceolotto G, Gallo A, Sartori M, Valente R, Baritono E, Semplicini A et al. Hyperglycemia acutely increases monocyte extracellular signal-regulated kinase activity in vivo in humans. J Clin Endocrinol Metab 2001;86:1301-5.
26. Okouchi M, Okayama N, Imai S, Omi H, Shimizu M, Fukutomi T et al. High insulin enhances neutrophil transendothelial migration through increasing surface expression of platelet endothelial cell adhesion molecule-1 via activation of mitogen activated protein kinase. Diabetologia 2002;45:1449-56.
27. Ceolotto G, Bevilacqua M, Papparella I, Baritono E, Franco L, Corvaja C et al. Insulin generates free radicals by an NAD(P)H, phosphatidylinositol 3'-kinase-dependent mechanism in human skin fibroblasts ex vivo. Diabetes 2004;53:1344-51.
28. O'Hare JA, Minaker KL, Meneilly GS, Rowe JW, Pallotta JA, Young JB. Effect of insulin on plasma norepinephrine and 3,4-dihydroxyphenylalanine in obese men. Metabolism 1989;38:322-9.
29. Muntzel MS, Anderson EA, Johnson AK, Mark AL. Mechanisms of insulin action on sympathetic nerve activity. Clin Exp Hypertens 1995;17:39-50.
30. Vollenweider L, Tappy L, Owlya R, Jéquier E, Nicod P, Scherrer U. Insulin-induced sympathetic activation and vasodilation in skeletal muscle: effects of insulin resistance in lean subjects. Diabetes 1995;44:641-5.
31. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-9.
32. Boden G, Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 1995;96:1261-8.
33. Caglayan E, Blaschke F, Takata Y, Hsueh WA. Metabolic syndrome-interdependence of the cardiovascular and metabolic pathways. Curr Opin Pharmacol 2005;5:135-42.
34. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-a in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
35. Yki-Jarvinen H. Fat in the liver and insulin resistance. Ann Med 2005;37:347-56.
36. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003;108:2460-6.
37. Chandola T, Brunner E, Marmot M. Chronic stress at work and the metabolic syndrome: prospective study. BMJ 2006;332:521-5. Epub 2006 Jan 20.
38. Reynolds RM, Walker BR. Human insulin resistance: the role of glucocorticoids. Diabetes Obes Metab 2003;5:5-12.
39. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004;25:831-66.
40. Kim JA, Koh KK, Quon MJ. The union of vascular and metabolic actions of insulin in sickness and in health. Arterioscler Thromb Vasc Biol 2005;25:889-91.
41. Tataranni PA, Ortega E. A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes? Diabetes 2005;54:917-27.
42. Berg AH, Lin Y, Lisanti MP, Scherer PE. Adipocyte differentiation induces dynamic changes in NF-kappaB expression and activity. Am J Physiol Endocrinol Metab 2004;287:E1178-88. Epub 2004 Jul 13.
43. Xu, H. Barnes GT, Yang Q, Tan G, Yang D, Chou CJ et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-30.
44. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808.
45. Dandona P, Aljada A, Chaudhuri A Mohanty P, Garg R. Metabolic syndrome. A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005;111:1448-54.
46. Perschinka H, Mayr M, Millonig G, Mayerl C, van der Zee R, Morrison SG et al. Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:1060-5.
47. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003;426:895-9.
48. Hotamisligil GS. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 2005;54 Suppl 2:S73-8.
49. Ozcan U, Cao Q Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306:457-61.